372 CHAPTER 4.3 References 1. SIMPATHY-consortium. Polypharmacy Management by 2030: a patient safety challenge. 2017. https://ec.europa.eu/chafea/health/newsroom/news/documents/polypharmacyhandbook-second-edition_en.pdf. Accessed 30 May 2022. 2. World Health Organization. WHO global patient safety challenge: medication without harm 2017. https://www.who.int/publications/i/item/WHO-HIS-SDS-2017.6. Accessed 3 Aug 2022. 3. World Health Organization. WHO Technical Report; Medication Safety in Polypharmacy. 2019. https://www.who.int/publications/i/item/WHO-UHC-SDS-2019.11. Accessed 6 Jun 2022. 4. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study. Lancet 2012;380:37–43. https://doi.org/10.1016/S01406736(12)60240-2. 5. Johnston MC, Crilly M, Black C, Prescott GJ, Mercer SW. Defining and measuring multimorbidity: A systematic review of systematic reviews. Eur J Public Health 2019;29(1):182–9. https://doi.org/10.1093/eurpub/cky098. 6. Bezerra de Souza DL, Oliveras-Fabregas A, Espelt A, Bosque-Prous M, de Camargo Cancela M, Teixidó-Compañó E, et al. Multimorbidity and its associated factors among adults aged 50 and over: A cross-sectional study in 17 European countries. PLoS One 2021;16:1–10. https://doi.org/10.1371/journal.pone.0246623. 7. Moen J, Antonov K, Larsson CA, Lindblad U, Nilsson JLG, Råstam L, et al. Factors associated with multiple medication use in different age groups. Ann Pharmacother 2009;43(12):1978–85. https://doi.org/10.1345/aph.1M354. 8. Fortin M, Lapointe L, Hudon C, Vanasse A, Ntetu AL, Maltais D. Multimorbidity and quality of life in primary care: A systematic review. Health Qual Life Outcomes 2004;20:2:51. https://doi.org/10.1186/1477-7525-2-51. 9. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017;17:1–10. https://doi.org/10.1186/ s12877-017-0621-2. 10. Mehta RS, Kochar BD, Kennelty K, Ernst ME, Chan AT. Emerging approaches to polypharmacy among older adults. Nat Aging 2021;1:347–56. https://doi.org/10.1038/ s43587-021-00045-3. 11. Linkens AEMJH, Milosevic V, van der Kuy PHM, Damen-Hendriks VH, Mestres Gonzalvo C, Hurkens KPGM. Medication-related hospital admissions and readmissions in older patients: an overview of literature. Int J Clin Pharm 2020;42:1243–51. https://doi. org/10.1007/s11096-020-01040-1. 12. Pereira F, Verloo H, Zhivko T, Di Giovanni S, Meyer-Massetti C, Von Gunten A, et al. Risk of 30-day hospital readmission associated with medical conditions and drug regimens of polymedicated, older inpatients discharged home: A registry-based cohort study. BMJ Open 2021;11:1–12. https://doi.org/10.1136/bmjopen-2021-052755. 13. Beuscart J, Knol W, Cullinan S, Schneider C, Dalleur O, Boland B, et al. International core outcome set for clinical trials of medication review in multi-morbid older patients with polypharmacy. BMC Med 2018;21:1–9. https://doi.org/10.1186/s12916-018-1007-9. 14. Thevelin S, Spinewine A, Beuscart JB, Boland B, Marien S, Vaillant F, et al. Development of a standardized chart review method to identify drug-related hospital admissions in older people. Br J Clin Pharmacol 2018. https://doi.org/10.1111/bcp.13716.
RkJQdWJsaXNoZXIy MTk4NDMw